NCT05059301 - A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above | Biotech Hunter

Enrollment

770

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

January 24, 2022

Study Completion Date

June 30, 2022

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF3 OA investigational vaccine

One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.

Trial Locations (19)

27408

GSK Investigational Site, Greensboro

30519

GSK Investigational Site, Buford

34142

GSK Investigational Site, Immokalee

34613

GSK Investigational Site, Brooksville

39465

GSK Investigational Site, Petal

55402

GSK Investigational Site, Minneapolis

68144

GSK Investigational Site, Omaha

77058

GSK Investigational Site, Houston

06708

GSK Investigational Site, Waterbury

V5Z 1K3

GSK Investigational Site, Vancouver

E1G1A7

GSK Investigational Site, Moncton

B2N 1L2

GSK Investigational Site, Truro

M3J 2C5

GSK Investigational Site, Toronto

G1W 4R4

GSK Investigational Site, Québec

J6E 2B4

GSK Investigational Site, Saint-Charles-Borromée

J1J 2G2

GSK Investigational Site, Sherbrooke

SE-631 88

GSK Investigational Site, Eskilstuna

SE-371 79

GSK Investigational Site, Karlskrona

SE-752 37

GSK Investigational Site, Uppsala